Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Depreciation & Amortization (CF) (2021 - 2025)

PAVmed (PAVM) has 5 years of Depreciation & Amortization (CF) data on record, last reported at $22000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $22000.0; the TTM value through Sep 2025 reached $156000.0, changed N/A, while the annual FY2024 figure was $1.2 million, 59.14% down from the prior year.
  • Depreciation & Amortization (CF) reached $22000.0 in Q3 2025 per PAVM's latest filing, roughly flat from $22000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $815000.0 in Q2 2022 and bottomed at $10000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $369777.8, with a median of $260500.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 8050.0% in 2022, then crashed 92.79% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $166000.0 in 2021, then surged by 337.35% to $726000.0 in 2022, then decreased by 0.14% to $725000.0 in 2023, then crashed by 90.48% to $69000.0 in 2024, then plummeted by 68.12% to $22000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $22000.0 in Q3 2025, $22000.0 in Q2 2025, and $43000.0 in Q1 2025.